MSB 2.98% $1.47 mesoblast limited

Cell Therapy News/Articles, page-5763

  1. 1,609 Posts.
    lightbulb Created with Sketch. 1691
    All of the evidence points directly to Rem-L having so many positive effects--and ARDS and ARDS treatment having so many more negative effects--even with improved SOC over the last few months leading to decreased mortality rates overall.

    Every day, I am that much more confident we are going to be able to show overwhelming efficacy from those first interim results.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.